Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma
Phase II Study of Low Intensity Allogeneic Transplantation in Mantle Cell Lymphoma
RATIONALE: Giving chemotherapy and monoclonal antibody therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
PURPOSE: This phase II trial is studying donor stem cell transplant in treating patients with mantle cell lymphoma.
研究概览
详细说明
OBJECTIVES:
Primary
- Determine progression-free survival in patients with mantle cell lymphoma undergoing low-intensity allogeneic stem cell transplantation.
Secondary
- Determine overall survival of these patients.
- Determine the toxicity by way of adverse event profile of this regimen in these patients.
OUTLINE: This is a multicenter study.
- Reduced intensity conditioning: Patients receive carmustine IV over 2 hours on day -6, etoposide IV over 1 hour and cytarabine IV over 15 minutes on days -5 to -2, alemtuzumab IV over 2 hours on days -5 to -1, and melphalan IV on day -1.
- Donor stem cell transplant: Patients undergo stem cell transplantation on day 0 with filgrastim (G-CSF)-mobilized peripheral blood stem cells or bone marrow stem cells.
- Graft-versus-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV or orally on day -1 to 30 and taper to day 100.
- Donor lymphocyte infusion (DLI) therapy: Patients with evidence of disease progression, mixed chimerism, or low level residual disease undergo DLI every 3 months for up to 15 months in the absence of GVHD.
After completion of study, patients are followed every 3 months for 2 years.
研究类型
注册 (预期的)
阶段
- 阶段2
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS:
- Histologically confirmed diagnosis of mantle cell lymphoma
- No relapsed or progressive disease
- Achieved at least a partial remission following induction chemotherapy
- HLA-matched donor available
- Blood samples from both patient and donor available for chimerism studies
- No central nervous system involvement
PATIENT CHARACTERISTICS:
- ECOG performance status 2-4
- Considered fit for transplant by treating physician
- Serum bilirubin ≤ 1.5 times upper limit of normal
- Alkaline phosphatase ≤ 2 times normal
- Creatinine clearance ≥ 50 mL/min
- Ejection fraction > 50% (no inadequate cardiac function)
- Not pregnant or nursing
- Negative pregnancy test
- No symptomatic respiratory compromise
- No serious concurrent disease which would preclude allograft
- No known serological positivity for hepatitis B, hepatitis C, or HIV
- No history of a psychological illness or condition that would affect compliance
- No previous malignancy within the past 5 years except nonmelanoma skin tumors or stage 0 (in situ) cervical carcinoma
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
研究衡量的是什么?
主要结果指标
结果测量 |
---|
无进展生存期
|
次要结果测量
结果测量 |
---|
毒性
|
总生存期
|
合作者和调查者
调查人员
- 首席研究员:Simon Rule, MD、Derriford Hospital
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- UCL-BRD-07-137
- CDR0000597903 (注册表标识符:PDQ (Physician Data Query))
- EUDRACT 2007-003081-18
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
阿糖胞苷的临床试验
-
Samsung Medical Center未知
-
The First Affiliated Hospital with Nanjing Medical...Huai'an First People's Hospital; Yancheng First People's Hospital招聘中